Development of a Physiologically Based Pharmacokinetic Population Model for Diabetic Patients and Its Application to Understand Disease-drug-drug Interactions

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2024 May 31

PMID 38819713

Authors

Yafen Li

Xiaonan Li

Miao Zhu

Huan Liu

Zihan Lei

Xueting Yao

Dongyang Liu

Affiliations

Soon will be listed here.

Abstract

Introduction: The activity changes of cytochrome P450 (CYP450) enzymes, along with the complicated medication scenarios in diabetes mellitus (DM) patients, result in the unanticipated pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interactions (DDIs). Physiologically based pharmacokinetic (PBPK) modeling has been a useful tool for assessing the influence of disease status on CYP enzymes and the resulting DDIs. This work aims to develop a novel diabetic PBPK population model to facilitate the prediction of PK and DDI in DM patients.

Methods: First, mathematical functions were constructed to describe the demographic and non-CYP physiological characteristics specific to DM, which were then incorporated into the PBPK model to quantify the net changes in CYP enzyme activities by comparing the PK of CYP probe drugs in DM versus non-DM subjects.

Results: The results show that the enzyme activity is reduced by 32.3% for CYP3A4/5, 39.1% for CYP2C19, and 27% for CYP2B6, while CYP2C9 activity is enhanced by 38% under DM condition. Finally, the diabetic PBPK model was developed through integrating the DM-specific CYP activities and other parameters and was further used to perform PK simulations under 12 drug combination scenarios, among which 3 combinations were predicted to result in significant PK changes in DM, which may cause DDI risks in DM patients.

Conclusions: The PBPK modeling applied herein provides a quantitative tool to assess the impact of disease factors on relevant enzyme pathways and potential disease-drug-drug-interactions (DDDIs), which may be useful for dosing regimen optimization and minimizing the DDI risks associated with the treatment of DM.

References

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan B . IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021; 183:109119. PMC: 11057359. DOI: 10.1016/j.diabres.2021.109119. View

Rendell M, Lassek W, Ross D, Smith C, Kernek S, Williams J . A pharmaceutical profile of diabetic patients. J Chronic Dis. 1983; 36(2):193-202. DOI: 10.1016/0021-9681(83)90093-0. View

Angiolillo D, Jakubowski J, Ferreiro J, Tello-Montoliu A, Rollini F, Franchi F . Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol. 2014; 64(10):1005-14. DOI: 10.1016/j.jacc.2014.06.1170. View

Dostalek M, Sam W, Paryani K, Macwan J, Gohh R, Akhlaghi F . Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. Clin Pharmacokinet. 2012; 51(9):591-606. DOI: 10.2165/11632690-000000000-00000. View

Iida M, Ikeda M, Kishimoto M, Tsujino T, Kaneto H, Matsuhisa M . Evaluation of gut motility in type II diabetes by the radiopaque marker method. J Gastroenterol Hepatol. 2000; 15(4):381-5. DOI: 10.1046/j.1440-1746.2000.02076.x. View

Dostalek M, Akhlaghi F, Puzanovova M . Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet. 2012; 51(8):481-99. DOI: 10.2165/11631900-000000000-00000. View

Triantafyllou K, Kalantzis C, Papadopoulos A, Apostolopoulos P, Rokkas T, Kalantzis N . Video-capsule endoscopy gastric and small bowel transit time and completeness of the examination in patients with diabetes mellitus. Dig Liver Dis. 2007; 39(6):575-80. DOI: 10.1016/j.dld.2007.01.024. View

Okabe N, Hashizume N . Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism. Biol Pharm Bull. 1994; 17(1):16-21. DOI: 10.1248/bpb.17.16. View

Tziomalos K, Athyros V . Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis. Rev Diabet Stud. 2015; 12(1-2):110-8. PMC: 5397986. DOI: 10.1900/RDS.2015.12.110. View

10.

Wang Z, Yang H, Xu J, Zhao K, Chen Y, Liang L . Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters. Drug Metab Dispos. 2019; 47(10):1066-1079. DOI: 10.1124/dmd.118.085902. View

11.

Edginton A, Theil F, Schmitt W, Willmann S . Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol. 2008; 4(9):1143-52. DOI: 10.1517/17425255.4.9.1143. View

12.

Perry C, Davis G, Conner T, Zhang T . Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview. Curr Pharmacol Rep. 2020; 6(3):71-84. PMC: 7214223. DOI: 10.1007/s40495-020-00212-x. View

13.

Barter Z, Tucker G, Rowland-Yeo K . Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2013; 52(12):1085-100. DOI: 10.1007/s40262-013-0089-y. View

14.

Zhou W, Johnson T, Bui K, Cheung S, Li J, Xu H . Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children. Clin Pharmacol Ther. 2017; 104(1):188-200. DOI: 10.1002/cpt.905. View

15.

Alqahtani F, Asiri A, Zamir A, Rasool M, Alali A, Alsanea S . Predicting Hydroxychloroquine Clearance in Healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach. Pharmaceutics. 2023; 15(4). PMC: 10140819. DOI: 10.3390/pharmaceutics15041250. View

16.

Jiang X, Zhuang Y, Xu Z, Wang W, Zhou H . Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6. AAPS J. 2016; 18(3):767-76. PMC: 5256608. DOI: 10.1208/s12248-016-9890-5. View

17.

Edginton A, Willmann S . Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin Pharmacokinet. 2008; 47(11):743-52. DOI: 10.2165/00003088-200847110-00005. View

18.

Ghobadi C, Johnson T, Aarabi M, Almond L, Allabi A, Rowland-Yeo K . Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin Pharmacokinet. 2011; 50(12):809-22. DOI: 10.2165/11594420-000000000-00000. View

19.

Harreiter J, Roden M . [Diabetes mellitus: definition, classification, diagnosis, screening and prevention (Update 2023)]. Wien Klin Wochenschr. 2023; 135(Suppl 1):7-17. PMC: 10133036. DOI: 10.1007/s00508-022-02122-y. View

20.

Wilson G, Wilkins G, Cotter J, Lamberts R, Lal S, Baldi J . Impaired ventricular filling limits cardiac reserve during submaximal exercise in people with type 2 diabetes. Cardiovasc Diabetol. 2017; 16(1):160. PMC: 5735887. DOI: 10.1186/s12933-017-0644-1. View